Breast Cancer Index® (BCI)

  • Molecular

Breast Cancer Index (BCI) is an RT-PCR assay performed on FFPE breast tumor tissue that integrates two gene expression-based biomarkers: 1) the HOXB13:IL17BR ratio (H/I), which is associated with tumor responsiveness to endocrine therapy; and 2) Molecular Grade Index (MGI), which consists of the average expression of five cell cycle-associated genes (BUB1B, CENPA, NEK2, RACGAP1 and RRM2) and provides quantitative and objective molecular assessment of tumor proliferative status. BCI is offered by Biotheranostics, a Hologic company.

Level of Service

  • Global
New York Approved: Yes

Specimen Requirements

Testing is performed on breast primary invasive tumor. FFPE tissue: Paraffin block is preferred. Alternatively, send 3-4 unstained, 10 micron thick sections on glass slides (an area of tumor that contains >40% neoplastic cells) and one H&E-stained slide. Note: Cases with the following clinical or specimen characteristics are not acceptable: post-treatment (adjuvant or neoadjuvant) specimens, fine needle aspirations (FNA), fresh or frozen tissue, both ER- and PR-, positive nodes, microinvasive carcinoma, metaplastic or metastatic breast cancer, carcinosarcoma, sarcoma, neuroendocrine carcinoma, adenoid cystic carcinoma, phyllodes tumor, male gender, T4 tumor, no evidence of invasive (ductal, lobular or mixed ductal lobular) carcinoma, biopsy site of chest wall, skin, axilla or lymph node.

Storage and Transportation

Storage & Transportation: Use cold pack for transport, making sure cold pack is not in direct contact with specimen. NYS clients please provide date and time of Collection.

CPT Code(s)*

Please contact Biotheranostics, Inc. at 877-886-6739.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.

Last Updated: January 27, 2025

Get in touch

Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.